Management team

Jesper Boysen - E-MBA

Chief Executive Officer

Jesper has been CEO of Nanovi since September 2017. He has extensive strategic, commercial and business development experience from previous senior management positions in the MedTech industry. He has been EVP at Mediq BV, CEO at Mediq Danmark, CEO at SDC DanDisc A/S and Nordic general manager at Mølnlycke Health Care. Jesper is founder and CEO of Micocou Holding, a MedTech investment company. He holds an E-MBA in Business Administration and Graduate Diplomas in Finance and Marketing.

Hanne Leth Hillman - MSc, Intl. Finance

Chief Financial Officer

Hanne joined Nanovi as CFO in May 2017. She spans competences in the fields of finance, capital and investor market relations and corporate communication. She has +10 years of experience from previous senior management positions in publicly listed life science companies and +10 years of experience from life science investment banking, corporate finance and equity research. Hanne holds a Master of Science in Business Administration and International Finance.

Hsiao-Qing Chow - MSc

Director, Regulatory Affairs

Chow joined Nanovi in 2016 as Senior Regulatory Affairs Manager and was appointed to Director of Regulatory Affairs in June 2018 with responsibility for Regulatory Affairs and Quality Assurance including design control and risk management. Chow has +7 years of experience from previous regulatory and quality management positions in the medical device industry, including several years with Coloplast. Chow holds a Master of Science in Pharmacy.

Michael Wrang Mortensen - MSc, PhD

Director, Development & Supply

Michael joined Nanovi in July 2018. He has +10 years of previous experience from the MedTech industry, including several years with Ferrosan Medical Devices A/S collaborating closely with Ethicon Biosurgery Inc., Johnson & Johnson. He has held management and leadership positions in global R&D teams as well as in commercial development and operational projects in both small and international organizations. Michael holds a Master of Science in Engineering from the Danish Technical University and a PhD degree in Chemistry as well as an E-MBA from the AVT Business School in Copenhagen.

Dan Calatayud – MD

Director, Medical Affairs

Dan joined Nanovi in April 2020 as Director of Medical Affairs. He has +12 years of combined experience from working as a physician and researcher and from the medical device industry.
Dan’s broad clinical experience spans various medical and surgical departments, family medicine, mental health as well as intensive care. His scientific activities have focused on translational research in gastrointestinal cancers. Dan holds a medical degree from The University of Copenhagen and has taken courses in business administration from Copenhagen Business School.

Board of Directors

Simon Hesse Hoffmann


Simon joined the Board in May 2018 and became Chairman of the Board in December 2018. He is Director of JHO Holding ApS and has previously held financial positions in several publicly listed Danish companies, including a position as Head of Group Treasury in DFDS A/S. His experience spans financial management, governance and reporting as well as budgeting and corporate funding. Simon is member of the board in HolmeTex ApS and WireOnAir A/S, and he is Chairman of the Board in the SMIL Foundation (SMILfonden) . Simon holds a Master of Science in Finance and International Business.

Michael Sandhu

Vice Chairman

Michael was elected to Nanovi’s board in November 2019. As a cancer therapy market specialist, Michael has +30 years of international experience in the field of radiation therapy, mainly from three decades of tenure with Varian Medical Systems, a world leading supplier of specialized radiotherapy equipment. Michael has held leadership positions in global cancer and radiation therapy market development and access, customer and partner relations management and commercialization. He is CEO and owner of remediumRT AG, a cancer care consultancy company, and Board Member of the Global Access to Cancer Care Foundation. Michael holds a BSc (Hons) in Medical Sciences from the University of Bradford.

Brian Holch Kristensen

Brian was elected to Nanovi’s board in May 2021. He holds the position as Chief Innovation Officer at Bispebjerg Hospital, Copenhagen and brings into Nanovi a wealth of experience and international connections in the field of innovative radiation oncology. Brian was previously Chief Physicist at the Radiotherapy Department at Herlev Hospital, also Copenhagen, where he has spent more than 15 years in leading roles focusing on the development and implementation of radical and novel radiation treatment. Throughout his career, Brian has promoted innovation in radiation therapy through collaborations and been a key facilitator for a number of successful public-private partnerships with major radiation equipment suppliers, incl. Varian, BrainLab and GE.

Thomas L. Andresen

Thomas is the founder of Nanovi. He is Professor and head of the Department of Health Technology at the Technical University of Denmark. Thomas has more than 20 years of research and development experience in biomedical engineering with a primary focus on cancer and is author on more than 160 research or review articles and on 40 pending and issued patents. Thomas is a serial MedTech/biotech entrepreneur, and he has served as Chief Scientific Officer and Head of R&D with several companies including Torque Therapeutics Inc, a Boston, US based biopharmaceutical company that develops cell therapies for cancer.

Ole Kring

Ole joined the Board in December 2018. He is Investment Director in Vækstfonden’s Life Science team and represents Vækstfonden on the Board of Directors. Ole has extensive management, commercial and operational experience. He is the founder of Scandinavian Micro Biodevices, where he was CEO for 12 years, including after the company was acquired by Zoetis Inc. in 2016. Ole holds a Master of Science in Economy & Business Administration.

Jesper Boysen

Jesper is CEO of Nanovi
(see his biography under Management team).